aTyr Pharma, Inc.

NasdaqCM:ATYR 주식 보고서

시가총액: US$246.3m

aTyr Pharma 미래 성장

Future 기준 확인 5/6

aTyr Pharma은 연간 수입과 매출이 각각 65.7%와 73.6% 증가할 것으로 예상되고 EPS는 연간 67.5%만큼 증가할 것으로 예상됩니다.

주요 정보

65.7%

수익 성장률

67.5%

EPS 성장률

Biotechs 수익 성장28.0%
매출 성장률73.6%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트29 Oct 2024

최근 미래 성장 업데이트

Recent updates

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

수익 및 매출 성장 예측

NasdaqCM:ATYR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202664-38-65-1117
12/31/20255-64-57-647
12/31/20240-65-58-677
6/30/20241-58-64-63N/A
3/31/20241-54-58-55N/A
12/31/20230-50-37-33N/A
9/30/202311-43-38-33N/A
6/30/202310-45-40-35N/A
3/31/202310-45-35-32N/A
12/31/202210-45-44-42N/A
9/30/2022N/A-46-40-40N/A
6/30/2022N/A-41-39-39N/A
3/31/2022N/A-39-38-37N/A
12/31/2021N/A-34-33-33N/A
9/30/20212-30-31-30N/A
6/30/20212-29-25-24N/A
3/31/20212-25-23-23N/A
12/31/202010-16-16-15N/A
9/30/20209-17-15-15N/A
6/30/20209-16-14-14N/A
3/31/20208-16-12-12N/A
12/31/20190-24-20-20N/A
9/30/20190-24-20-20N/A
6/30/20190-25-22-22N/A
3/31/2019N/A-30-27-27N/A
12/31/2018N/A-35-32-31N/A
9/30/2018N/A-40-37-37N/A
6/30/2018N/A-44-40-39N/A
3/31/2018N/A-45N/A-39N/A
12/31/2017N/A-48N/A-42N/A
9/30/2017N/A-49N/A-44N/A
6/30/2017N/A-52N/A-50N/A
3/31/2017N/A-55N/A-54N/A
12/31/2016N/A-58N/A-53N/A
9/30/2016N/A-62N/A-51N/A
6/30/2016N/A-59N/A-46N/A
3/31/2016N/A-55N/A-43N/A
12/31/2015N/A-48N/A-37N/A
9/30/2015N/A-38N/A-33N/A
6/30/2015N/A-33N/A-29N/A
3/31/2015N/A-28N/A-23N/A
12/31/2014N/A-25N/A-23N/A
9/30/2014N/A-24N/A-21N/A

애널리스트 미래 성장 예측

수입 대 저축률: ATYR 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ATYR (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ATYR 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ATYR 의 수익(연간 73.6% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: ATYR 의 수익(연간 73.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ATYR 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견